Bellerophon Ther­a­peu­tics lets al­most all em­ploy­ees go, looks for deals in wake of PhI­II flop

Less than a month af­ter ad­mit­ting fail­ure in a high­ly an­tic­i­pat­ed tri­al of its on­ly pro­gram, Bellerophon Ther­a­peu­tics is wav­ing the white flag.

The biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER